About

Betathera Ltd spun out from TRN – The Research Network Ltd in 2022 in collaboration with the University of Wollongong. All rights and data related to Pol III β site inhibitors from the previous six years were transferred to Betathera Ltd to build a dedicated and specialised focus on this project.  The Betathera team have extensive experience in the antibiotic therapeutic area and are further building the Betathara team to bring in additional expertise to progress the current leads.